Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

The conversion of kidney transplant patients to tacrolimus from cyclosporine because of refractory rejection or significant cyclosporine toxicity,

Go back to Resources

The conversion of kidney transplant patients to tacrolimus from cyclosporine because of refractory rejection or significant cyclosporine toxicity,

Authors:

Location:

Go back to Resources

Steady improvement in post 1 year half-life of pediatric renal transplants,

Go back to Resources

Steady improvement in post 1 year half-life of pediatric renal transplants,

Authors:

Location:

Go back to Resources

Practical Issues in the Design and Analysis of the Quality of Life Study in the Unrelated Donor Marrow Transplantation Trial.

Go back to Resources

Practical Issues in the Design and Analysis of the Quality of Life Study in the Unrelated Donor Marrow Transplantation Trial.

Authors:

Location:

Go back to Resources

Post transplant diabetes mellitus in pediatric renal transplant recipients: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Go back to Resources

Post transplant diabetes mellitus in pediatric renal transplant recipients: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Authors:

Location:

Go back to Resources

Plasma concentrations and pharmacokinetics of dimethylsulfoxide and metabolites in patients undergoing peripheral stem-cell transplants

Go back to Resources

Plasma concentrations and pharmacokinetics of dimethylsulfoxide and metabolites in patients undergoing peripheral stem-cell transplants

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Much Ado About Not Enough Data: Breast Cancer Transplantation in the 90's

Go back to Resources

Much Ado About Not Enough Data: Breast Cancer Transplantation in the 90's

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Malignancy and post-transplant lymphoproliferative disorder (PTLD) in pediatric renal transplant recipients: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Go back to Resources

Malignancy and post-transplant lymphoproliferative disorder (PTLD) in pediatric renal transplant recipients: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Authors:

Location:

Go back to Resources

Living unrelated renal transplantation in children: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Go back to Resources

Living unrelated renal transplantation in children: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Limited sampling strategies for predicting doxorubicin (DOX) and paclitaxel (PTX) areas under concentration x time curve (AUC), when DOX and PTX are given in combination,

Go back to Resources

Limited sampling strategies for predicting doxorubicin (DOX) and paclitaxel (PTX) areas under concentration x time curve (AUC), when DOX and PTX are given in combination,

Authors:

Go back to Resources

Intrarenal expression of cytotoxic attack molecules during acute rejection of renal allografts in pediatric recipients.

Go back to Resources

Intrarenal expression of cytotoxic attack molecules during acute rejection of renal allografts in pediatric recipients.

Authors:

Location:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 108
  • Page 109
  • Page 110
  • Page 111
  • Current page 112
  • Page 113
  • Page 114
  • Page 115
  • Page 116
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions